Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective studyXiang Ren, Ruibao Chen, Ying Zhan et al.|BMC Urology|2022Cited by 23
Standardized Incidence Rate, Risk and Survival Outcomes of Second Primary Malignancy Among Renal Cell Carcinoma Survivors: A Nested Case-Control StudyZhixian Wang, Yisheng Yin, Jing Wang et al.|Frontiers in Oncology|2021Cited by 12
A Multilayer Nanofibrous Mat for the Topical Chemotherapy of the Positive Margin in Bladder CancerJing Wang, Minglong Wu, Yunpeng Zhu et al.|Tissue Engineering Part A|2022Cited by 7
Docetaxel-Loaded Electrospun Nanofibrous Mats for Local Chemotherapy Targeting Positive Surgical Margins in Prostate CancerXing Li, Kun Yuan, Yisheng Yin et al.|Molecular Pharmaceutics|2025Cited by 6
Qualification of Necroptosis-Related lncRNA to Forecast the Treatment Outcome, Immune Response, and Therapeutic Effect of Kidney Renal Clear Cell CarcinomaYisheng Yin, Yiqun Tian, Xiang Ren et al.|Journal of Oncology|2022Cited by 4